Represents aggregate offering price pursuant to an effective shelf registration statement.

No definition available.

Name:	nbrv_AggregateOfferingPriceAuthorizedAmount
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash inflow from the additional capital contribution to the entity before deduction of issuance expenses.

+ References

No definition available.

+ Details

Name:	nbrv_GrossProceedsFromIssuanceOfCommonStock
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

n/a

+ References

No definition available.

+ Details

Name:	nbrv_LiquidityAbstract
Namespace Prefix:	nbrv_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Total number of representatives appointed.

+ References

No definition available.

+ Details

Name:	nbrv_NumberOfSalesRepresentatives
Namespace Prefix:	nbrv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Price of a single share and warrant of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	nbrv_ShareAndWarrantPrice
Namespace Prefix:	nbrv_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The value of shares available for sale remains unsold.

+ References

No definition available.

+ Details

Name:	nbrv_SharesAvailableForSaleValueRemainsUnsold
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

TEAE's adverse effect percentage of lefamulin-treated patients.

+ References

No definition available.

+ Details

Name:	nbrv_TeaeSAdverseEffectOfLefamulinTreatedPatientsPercentage
Namespace Prefix:	nbrv_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

TEAE's adverse effect percentage of moxifloxacin-treated patients.

+ References

No definition available.

+ Details

Name:	nbrv_TeaeSAdverseEffectOnPatientOfMoxifloxacinTreatedPatientsPercentage
Namespace Prefix:	nbrv_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of TEAE's leading to discontinuation were uncommon and observed in subjects in both treatment arms.

+ References

No definition available.

+ Details

Name:	nbrv_TeaeSLeadingToDiscontinuationEffectOnPatientPercentage
Namespace Prefix:	nbrv_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.

+ References

+ Details

Name:	us-gaap_CashCashEquivalentsAndShortTermInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Face amount or stated value per share of common stock.

+ References

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.

+ References

+ Details

Name:	us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258

+ Details

Name:	us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	srt_CounterpartyNameAxis=nbrv_JefferiesLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=nbrv_AtMarketOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=nbrv_OrdinaryStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbrv_InstitutionalInvestorsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=nbrv_PurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=nbrv_OrdinaryShareWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=nbrv_PreFundedWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nbrv_OpenMarketSaleAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Organization and Business Activities (Details) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended	6 Months Ended
	May 31, 2021 USD ($) shares	Nov. 30, 2020 employee	Sep. 30, 2020 employee	Mar. 31, 2021 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Jun. 30, 2020 USD ($)	Dec. 31, 2020 $ / shares	Jun. 30, 2019 USD ($)
Liquidity
Percentage of lefamulin-treated patients	4.00%
Percentage of moxifloxacin-treated patients	10.00%
Percentage of TEASE's leading to discontinuation were subjects in both treatment arms	5.00%
Cash, cash equivalents and short-term investments					$ 61,300
Number of sales representatives \| employee		60	15
Proceeds from at-the-market facility					$ 37,970	$ 3,688
Nominal value \| $ / shares					$ 0.01		$ 0.01
Jefferies LLC \| At-the-market offering
Liquidity
Maximum aggregate gross proceeds under the sales agreement								$ 50,000
Proceeds from at-the-market facility					$ 26,100
Net proceeds from sale of stock					$ 25,100
Jefferies LLC \| At-the-market offering \| Ordinary Shares
Liquidity
Number of shares issued \| shares					14,318,074
Purchasers \| Purchase agreement
Liquidity
Number of shares issued \| shares				9,761,010
Net proceeds from sale of stock				$ 23,400
Proceeds from Issuance or Sale of Equity				$ 25,400
Number of ordinary shares that can be purchased by warrant holders \| shares				4,880,505
Term				5 years
Ordinary Share Warrants \| Purchasers \| Purchase agreement
Liquidity
Number of ordinary shares that can be purchased by warrant holders \| shares				300,000
Nominal value \| $ / shares				$ 0.01
Share and warrant price \| $ / shares				2.4525
Exercise price \| $ / shares				$ 2.39
Pre-Funded Warrants \| Purchasers \| Purchase agreement
Liquidity
Number of ordinary shares that can be purchased by warrant holders \| shares				600,000
Share and warrant price \| $ / shares				$ 2.4425
Exercise price \| $ / shares				$ 0.01
Open Market Sale Agreement \| Jefferies LLC \| Ordinary Shares
Liquidity
Number of shares issued \| shares	5,925,699
Proceeds from at-the-market facility	$ 31,900
Aggregate gross sale proceeds for ordinary shares	33,700
Ordinary shares remained unsold	16,300
Open Market Sale Agreement \| Jefferies LLC \| Ordinary Shares \| Maximum
Liquidity
Aggregate gross sale proceeds for ordinary shares	$ 50,000